Prima BioMed announced that a research article titled "A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer" was published in the peer-reviewed Journal for ImmunoTherapy of Cancer. The research paper relates to the company's CAN-002 clinical trial of CVac in 28 patients with advanced epithelial ovarian cancer, completed in 2007. The clinical activity of CVac in ovarian cancer was evident from the CAN-002 data, based on decline or stabilization of CA125 in some patients. CVac was well tolerated by patients. The CAN-002 trial supported the continued clinical development of CVac.